Yaz Lawsuit Settlements 2013
Bayer tells their stockholders to expect more Yaz lawsuit settlements in 2013. Bayer now committed to spending millions settling Yaz lawsuits focuses on keeping stockholders happy with a strong bottom-line. The possibility of paying millions of dollars to potential victims in Yaz lawsuit claims does not however slow Bayer’s push to promote the product. Despite reports of deaths, women worldwide continue to buy Yaz and Yasmin making it one of the bestselling pharmaceuticals for the German manufacturer.
Is Bayer remorseful or just plain resourceful? Clinical data presented during Yaz lawsuit discovery as well as post marketing studies of the drospirenone containing oral contraceptives Yaz, Yasmin and Ocella suggest the potential of an increased risk of blood clot injury is present for women taking the drug. Bayer, in a brilliant move to contain any potential damage to their bottom-line announces Yaz settlements but offers no mea culpa.
Bayer’s Annual Report for their fiscal year 2012 is beautifully prepared. The art work as well as the content suggest global power and success but if read closely, includes interesting information for anyone with concerns about healthcare for women not only here at home but globally.
Any woman that has faced the need to prevent an unwanted pregnancy will tell you it may not be a choice. She may hate the idea of swallowing a birth control pill. However, preventing pregnancy may be an economic necessity for her family. It is also a billion dollar industry for drug manufacturers. In the face of necessity versus greed; who wins in the end? Ask any Yaz lawyer that has a client whose wife or mother died from a blood clot injury if obtaining a Yaz lawsuit made up for the lost life.
Emerging markets or exploitation? Bayer’s annual report for 2012 says “But sales from our Pharmaceuticals segment rose nonetheless, thanks to new products and continuing growth momentum in emerging markets.” The reports also says “Our largest segment in terms of sales – Pharmaceuticals– aims to become a leader in cardiovascular health and continue to expand the leading position it already holds in women’s healthcare.”
The term “emerging markets” was coined in 1981 and has come to mean different things to different people in business or economic terms. In general, everyone agrees that an emerging market is any country developing the ability to sustain and grow their economy. Typically, the per capita income is very low by US and Western European standards. Approval to market a drug more easily obtained so is less costly for the manufacture. Regulations for marketing and sales are less restrictive than in the US.
Women’s healthcare tends to remain under-developed in emerging markets. Personal injury may be taken less seriously. If that is true then of even more interest and concern is the question of “What happens if a woman in emerging markets such as India or China sustains a blood clot injury while taking Yaz, what will she do?” Will she be able to obtain a Yaz lawyer or file a Yaz lawsuit? Will she be entitled to a Yaz settlement and if so, how much (or little) will it cost Bayer? Will there ever be a Yaz recall? What is exploitation? You decide.
References
http://www.annualreport2012.bayer.com/en/bayer-annual-report-2012.pdfx
The post Yaz Lawsuit Settlements to Continue in 2013 appeared first on Todays Legal News.
